Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Cancer. 2020 Jul 16;126(18):4156–4167. doi: 10.1002/cncr.33033

Figure 4.

Figure 4.

Treatment-related adverse events (AEs) reported in ≥10% of treated patients in either arm (A) and median time to onset and resolution of nivolumab-related select (immune-related) AEs of any grade (B).

aNo patient reported a grade 3–4 treatment-related AE.

b<1% of patients experienced a grade 3 or 4 treatment-related AE.